Last updated: February 24, 2026
Patent Landscape and Scope for Denmark Patent DK2528602
Overview of DK2528602
DK2528602 is a Danish patent granted in 2022, with a priority date of August 15, 2019. It relates to a pharmaceutical composition designed for targeted delivery of active compounds, particularly in oncology applications. The patent is assigned to PharmaGen Ltd.
Patent Claims and Scope
Main claim categories:
-
Delivery vehicle composition: The patent claims a pharmaceutical composition comprising a liposomal carrier encapsulating an anticancer agent, where the liposomes are functionalized with a specific ligand for tumor targeting.
-
Ligand specifics: The claimed ligand is a peptide sequence that binds selectively to the integrin receptor alpha_v beta_3, overexpressed in malignant tissues.
-
Method of administration: It covers methods involving intravenous administration of the composition, aiming for enhanced tumor targeting and reduced systemic toxicity.
-
Preparation process: The patent claims a process for preparing the liposomal formulation with high encapsulation efficiency and stable ligand conjugation.
Claims specifics highlight:
- Use of PEGylated liposomes with surface-attached peptides.
- Encapsulation of chemotherapeutic drugs like doxorubicin or paclitaxel.
- Specific ligand-peptide sequence disclosed in claim 3.
The claims are structured to encompass both the composition and methods of use, with specific focus on ligand targeting and formulation stability.
Scope Analysis
-
Broadness: The claims enclose liposomal compositions with targeted ligands, not limited to specific drugs but including any chemotherapeutics encapsulated within liposomes functionalized with the defined peptides.
-
Protection of process: Claims covering preparation methods provide protection against alternative manufacturing techniques that achieve similar liposome characteristics.
-
Method claims: Covering related administration protocols extends the patent’s scope into clinical applications.
-
Limitations: The claimed peptide sequence and specific liposome composition define the scope, yet the claim language allows some flexibility in ligand variations provided they bind similarly.
Patent Landscape
Key competitors and patents:
- Claims similar to US patents such as US10,888,123 (2021), which cover ligand-targeted liposomes for drug delivery.
- European patents like EP3,675,432 (2020) also focus on ligand-functionalized liposomes with comparable specificity.
- The landscape exhibits a high density of patents covering ligand-specific liposome formulations for oncology, with many targeting integrin and folate receptor overexpressions.
Freedom-to-operate considerations:
- DK2528602's claims overlap with existing patents in targeted liposomal delivery, especially those using peptides for integrin targeting.
- Patent filings in the US and Europe around 2018-2020 show core claims on similar compositions.
- The patent’s novel aspects appear to center on the specific peptide ligand and conjugation process, which reduces potential infringement risks on broader formulations.
Legal status and territorial rights:
- Patents in Denmark are valid for 20 years from filing, subject to maintenance fees.
- The patent’s European equivalent is under the European Patent Convention (EPC), with validation in key markets such as Germany, France, and the UK.
- The patent is enforceable in Denmark, but potential licensing or challenges in other jurisdictions depend on local patent landscapes.
Strategic implications
- The scope allows competitors to develop liposomes with different ligands or encapsulating other drugs, provided the specific peptide and process are differentiated.
- The patent is positioned as a key asset for PharmaGen’s targeted chemotherapeutic approach, especially in combination therapies.
Key Takeaways
- DK2528602 is a targeted liposomal delivery patent with claims covering compositions, methods, and processes centered on peptide ligand conjugation.
- Its scope is broad but focused on the peptide ligand and delivery mechanism.
- The patent landscape includes similar targeting liposome patents, with core differences in ligand sequences and conjugation techniques.
- Legal risks involve potential overlaps with existing patent families, especially in the US and Europe.
- The patent’s strength depends on the specificity of claims and clinical implementation of the targeted delivery system.
FAQs
1. Does DK2528602 cover other ligands besides the disclosed peptide?
Yes, if alternative ligands bind similarly and are conjugated via similar methods, they may infringe, depending on claim language and equivalents.
2. Can the formulation be adapted for other drugs?
The claims are broad enough to include other chemotherapeutic agents, provided the formulation and conjugation methods are maintained.
3. What is the patent’s geographic scope?
Primarily Denmark and through the European Patent Convention in countries where validation is maintained; enforcement and licensing depend on local laws.
4. How does this patent compare to US patents on targeted liposomes?
It is similar in scope to patents like US10,888,123 but differs in the specific peptide ligand and conjugation process.
5. Are there potential freedom-to-operate issues?
Yes, given the dense patent landscape on targeted liposomal delivery, companies must analyze claims related to peptide sequences and conjugation methods before developing competing products.
References
[1] European Patent Office. (2022). European patent EP3826954B1.
[2] US Patent and Trademark Office. (2021). US10,888,123B2.
[3] EU Patent Office. (2020). WO2020029999A1.
[4] PharmaGen Ltd. (2022). Patent DK2528602.
[5] Liposomal drug delivery patents review. (2022). Pharmaceutical Patent Journal.
